Childhood Synovial Sarcoma
7
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (7)
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Ixabepilone in Treating Young Patients With Refractory Solid Tumors